statistiche ricercatore

Continente	#
EU - Europa	9.380
NA - Nord America	726
AS - Asia	469
SA - Sud America	66
Continente sconosciuto - Info sul continente non disponibili	33
AF - Africa	9
OC - Oceania	3
Totale	10.686

Nazione	#
IT - Italia	9.172
US - Stati Uniti d'America	703
SG - Singapore	170
CN - Cina	122
SE - Svezia	64
VN - Vietnam	57
BR - Brasile	41
DE - Germania	33
FR - Francia	27
IN - India	26
HK - Hong Kong	20
NL - Olanda	20
GB - Regno Unito	19
CA - Canada	16
FI - Finlandia	11
BD - Bangladesh	9
PL - Polonia	9
AR - Argentina	8
AT - Austria	7
KR - Corea	7
IQ - Iraq	6
IR - Iran	6
TR - Turchia	6
AE - Emirati Arabi Uniti	5
CO - Colombia	4
EC - Ecuador	4
ES - Italia	4
GR - Grecia	4
ID - Indonesia	4
IL - Israele	4
JP - Giappone	4
PH - Filippine	4
PK - Pakistan	4
TH - Thailandia	4
VE - Venezuela	4
AU - Australia	3
RU - Federazione Russa	3
SA - Arabia Saudita	3
UZ - Uzbekistan	3
ZA - Sudafrica	3
BB - Barbados	2
BH - Bahrain	2
CL - Cile	2
LT - Lituania	2
MA - Marocco	2
MX - Messico	2
NG - Nigeria	2
BO - Bolivia	1
CR - Costa Rica	1
EG - Egitto	1
IE - Irlanda	1
JM - Giamaica	1
KE - Kenya	1
LU - Lussemburgo	1
MN - Mongolia	1
MO - Macao, regione amministrativa speciale della Cina	1
NO - Norvegia	1
OM - Oman	1
PE - Perù	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	10.653

Nome	#
Molecular-biology-driven treatment for metastatic colorectal cancer	2.777
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment	1.371
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors	1.095
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	943
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression	881
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment	877
Uncovering key targets of success for immunotherapy in pancreatic cancer	729
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus	682
BRCA-mutant pancreatic ductal adenocarcinoma	623
Immune Checkpoint Inhibitors in the Treatment of HCC	598
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line	110
Totale	10.686

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	847	0	48	3	25	40	82	47	101	51	91	179	180
2022/2023	2.128	240	297	200	148	169	213	99	97	151	274	157	83
2023/2024	1.655	69	49	69	92	138	296	300	135	78	82	173	174
2024/2025	3.803	1.147	1.264	316	349	176	239	166	20	24	38	21	43
2025/2026	1.196	106	70	82	94	80	88	254	121	77	98	43	83
2026/2027	45	20	25	0	0	0	0	0	0	0	0	0	0
Totale													10.686

UNICA IRIS Institutional Research Information System